OpGen : Corporate Presentation (PDF)

OpGen

Corporate Overview

October 2020

Forward looking statements disclaimer

This presentation contains forward-looking statements that are subject to many risks and uncertainties. These statements, among other things, relate to our business strategy, goals and expectations concerning our products, future operations, prospects, plans and objectives of management. The words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will" and similar terms and phrases are used to identify forward-looking statements in this presentation. These statements and other statements regarding our future plans constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1955. Such statements are subject to risks and uncertainties that are often difficult to predict,

are beyond OpGen's control, and that may cause results to differ materially from expectations.

Factors that could cause results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and service offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the realization of expected synergies from our business combination transaction with Curetis GmbH, the successful integration of our company with the operations and business of Curetis GmbH and its subsidiaries and the implementation of the combined company's strategic and business goals and objectives, the impact of COVID- 19 on our operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the ability to comply with the complexities of operating a global business, the success of our commercialization efforts, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the date of this presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

©2020 OpGen, Inc.	2

OpGen and its group companies:

Striving to innovate molecular microbiology

Fast	Comprehensive	Smart	Easy

Rapid Pathogen	Broad Pathogen &	AI-Powered AMR	Sample-To-Answer
Detection For Life	Antimicrobial Resistance	Prediction &	Platforms
Threatening Infections	(AMR) Marker Coverage	Bioinformatics

©2020 OpGen, Inc.	3

Combined company's portfolio:

Synergistic products & capabilities

Unyvero Platform	Acuitas Tests &	Global Commercial	Ares Genetics NGS &
& Syndromic Tests	Acuitas Lighthouse	Presence	Bioinformatics

Unyvero FDA-cleared platform for lower respiratory tract infection (LRT & LRT BAL) as well as 5 CE IVD tests; Unyvero A30 RQ platform

in development

Acuitas AMR Gene Panel tests in clinical trials (Urine) and pending FDA clearance (isolates) to improve antibiotic decision making; Lighthouse knowledge base deployed for public health use

Direct sales in U.S., European and China distribution with partners; 18 distributors covering

43 countries; CoV-2 test kit distribution in EMEA

Ares Technology for AI-powered AMR prediction combining ARESdb with NGS; Strategic partnerships with globally leading IVD & pharma companies

©2020 OpGen, Inc.	4